Compile Data Set for Download or QSAR
maximum 50k data
Found 44 of ic50 data for polymerid = 50004037
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375312(US9908872, Compound (I-9))
Affinity DataIC50:  2.43nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375310(US9908872, Compound (I-8))
Affinity DataIC50:  5.33nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375276(US10597387, Compound (I-1) | US9908872, Compound (...)
Affinity DataIC50:  7.40nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50379186(CEP-11981 | CHEMBL2010872)
Affinity DataIC50:  14nMAssay Description:Inhibition of human TAK1 using ATP as substrateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375281(US10597387, Compound (I-4) | US9908872, Compound (...)
Affinity DataIC50:  22.8nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375307(US10597387, Compound (I-6) | US9908872, Compound (...)
Affinity DataIC50:  29.9nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439303(US10633348, Compound (A-17))
Affinity DataIC50:  45nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439318(US10633348, Compound (A-14))
Affinity DataIC50:  53.8nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375308(US10597387, Compound (I-7) | US9908872, Compound (...)
Affinity DataIC50:  56.5nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50086441(CHEMBL3426225 | US10266537, Compound 3)
Affinity DataIC50:  61nMAssay Description:Inhibition of human TAK1More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375280(US10597387, Compound (I-3) | US9908872, Compound (...)
Affinity DataIC50:  62.2nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439308(US10633348, Compound (A-6))
Affinity DataIC50:  63.5nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439309(US10633348, Compound (A-7))
Affinity DataIC50:  71.7nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439316(US10633348, Compound (A-12))
Affinity DataIC50:  76.2nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439305(US10633348, Compound (A-3))
Affinity DataIC50:  92nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439307(US10633348, Compound (A-5))
Affinity DataIC50:  100nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439304(US10633348, Compound (A-2))
Affinity DataIC50:  100nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375299(US10597387, Compound (I-5) | US9908872, Compound (...)
Affinity DataIC50:  117nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50604141(CHEMBL5188433)
Affinity DataIC50:  120nMAssay Description:Inhibition of TAK (unknown origin)More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50584720(CHEMBL5088153)
Affinity DataIC50:  126nMAssay Description:Inhibition of human TAK1 in presence of ATP by radiometric assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439319(US10633348, Compound (A-15))
Affinity DataIC50:  136nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50604140(CHEMBL5185000)
Affinity DataIC50:  260nMAssay Description:Inhibition of TAK (unknown origin)More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM438001(US10633348, Compound (A-1) | US10633348, Compound ...)
Affinity DataIC50:  364nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439317(US10633348, Compound (A-13))
Affinity DataIC50:  400nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM438001(US10633348, Compound (A-1) | US10633348, Compound ...)
Affinity DataIC50:  487nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439306(US10633348, Compound (A-4))
Affinity DataIC50:  591nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM400813(QL-X-138 | US10000483, Compound II-6)
Affinity DataIC50:  717nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439314(US10633348, Compound (A-18))
Affinity DataIC50:  1.75E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50245587(CHEMBL4077064 | US10000483, Compound II-4)
Affinity DataIC50: >3.30E+3nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM102620(BMX-IN-1 | N-[5-[9-[4-(methanesulfonamido)phenyl]-...)
Affinity DataIC50: >3.30E+3nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375307(US10597387, Compound (I-6) | US9908872, Compound (...)
Affinity DataIC50: >3.33E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439312(US10633348, Compound (A-9))
Affinity DataIC50:  7.31E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375276(US10597387, Compound (I-1) | US9908872, Compound (...)
Affinity DataIC50:  8.21E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439315(US10633348, Compound (A-11))
Affinity DataIC50: >1.00E+4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439313(US10633348, Compound (A-10))
Affinity DataIC50: >1.00E+4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375299(US10597387, Compound (I-5) | US9908872, Compound (...)
Affinity DataIC50: >1.00E+4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50386693(CHEMBL2048912)
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of N-terminus FLAG-tagged TAK1 expressed in baculovirus expression system using [gamma-33P]-ATP measured after 60 mins by scintillation co...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50334268(CHEMBL1642655 | CHEMBL2205637 | N-(6-(1H-imidazol-...)
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of TAK1More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50429867(CHEMBL2333365)
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of TAK1 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50432373(CHEMBL2348417)
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of N-terminal FLAG-tagged TAK1 (unknown origin) expressed in baculovirus expression system incubated for 5 mins prior to [gamma-33P]ATP ad...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50357884(CHEMBL1916359)
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of human TAK1More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50358430(CHEMBL1614725)
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of N-terminus flag-tagged TAK1 expressed in baculovirus infected insect cells using [gamma33P]ATP as substrate after 60 mins by scintillat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM357013(5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)...)
Affinity DataIC50:  5.00E+4nMAssay Description:The analyses were performed in U-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and subst...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50239229(CHEMBL4097255 | US10676460, Example 1)
Affinity DataIC50:  5.00E+4nMAssay Description:The analyses were performed in U-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and subst...More data for this Ligand-Target Pair
In DepthDetails US Patent